Physician profile
David Manly
NPI 1669817375
$6,226.48
in general payments reported to CMS, 2019-2025
27 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2021: $813 · 2022: $1,241 · 2023: $1,452 · 2024: $1,294 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,885.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,467.75 | 2019-2025 | Avvigo Guidance System, Opticross, Synergy |
| Abbott Laboratories | $1,294.52 | 2019-2025 | Xience Skypoint, Diamondback Coronary, Cardiomems |
| Cardiovascular Systems INC. | $699.35 | 2021-2022 | |
| Abiomed | $562.01 | 2022-2025 | Impella |
| Medtronic, INC. | $415.88 | 2021-2024 | Onyx Frontier, Symplicity G3 |
| Inari Medical, INC. | $279.42 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $243.64 | 2022-2025 | |
| Amgen INC. | $228.82 | 2021-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $118.92 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Atricure, INC. | $110.76 | 2022-2024 | |
| Philips North America LLC | $91.61 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und |
| Acist Medical Systems, INC. | $82.58 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.80 | 2023-2025 | Lifevest |
| Terumo Medical Corporation | $70.45 | 2025 | Angio-Seal, Metacross Otw, Glidesheath Slender |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.92 | 2022-2023 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $64.43 | 2022-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $56.51 | 2022-2025 | Camzyos |
| Penumbra, INC. | $55.15 | 2024 | Indigo System, Penumbra System |
| Pfizer INC. | $46.00 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $38.84 | 2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $33.82 | 2023 | Arcalyst |
| Cvrx, INC. | $26.02 | 2023 | Barostim Neo System |
| Esperion Therapeutics, INC. | $22.43 | 2025 | Nexletol |
| Shockwave Medical, INC | $22.11 | 2025 | |
| Alnylam Pharmaceuticals INC. | $19.72 | 2025 | Onpattro |
| Angiodynamics, INC. | $15.64 | 2021 | |
| Cardiva Medical, INC. | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Manly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.